The settlement agreement will extend market exclusivity for AbbVie's JAK inhibitor in the U.S. until 2037—providing pediatric ...

President Donald Trump is considering tariff exemptions for certain “non-patented” pharmaceuticals, though the White House ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

New York City has seen increased life sciences employment during the past decade as public funding and key projects like ...

Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of ...

Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a "smooth" approval process ...

As Novo Nordisk cuts 9,000 people from its organization in a restructuring effort, BioSpace looks back on the Danish pharma ...

The biopharma job market remains challenging, based on BioSpace data. In August, job postings live on the website dropped 32% ...

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Novo Nordisk also lowered its full-year profit growth guidance in connection with the restructuring effort. The pharma now ...

Former CDC director Susan Monarez and former chief medical officer Debra Houry will appear in front of the Senate HELP ...

These 27 markets, comprising countries across Asia, Europe and South America, together contributed some 12% of Lundbeck’s ...